B. Metzler seel. Sohn & Co. AG Boosts Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

B. Metzler seel. Sohn & Co. AG grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 35.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 34,049 shares of the company’s stock after buying an additional 8,909 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Dr. Reddy’s Laboratories were worth $538,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RDY. AIA Group Ltd grew its stake in shares of Dr. Reddy’s Laboratories by 441.7% in the fourth quarter. AIA Group Ltd now owns 145,150 shares of the company’s stock valued at $2,292,000 after buying an additional 118,357 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Van ECK Associates Corp increased its stake in Dr. Reddy’s Laboratories by 609.4% during the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock valued at $92,000 after purchasing an additional 5,015 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 400.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after purchasing an additional 427,573 shares during the period. Finally, World Investment Advisors LLC bought a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter worth about $3,459,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $12.37 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The firm has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.36 and a 1-year high of $16.89. The business’s fifty day moving average price is $13.33 and its two-hundred day moving average price is $14.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

RDY has been the topic of several research reports. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.